Results 221 to 230 of about 143,709 (342)

Evaluation of the role of silicon in alleviating cadmium stress in sorghum. [PDF]

Front Plant Sci
Gökdere H, Inci HŞ, Bilir B.
europepmc   +1 more source

Anti‐CD20 treatment in Primary Sjögren’s Syndrome [PDF]

, 2008
Kjetil Isaksen, Roland Jonsson, Roald Omdal   +2 more
openalex   +1 more source

CD20 (MS4A1) is differentially expressed in the lymph nodes of patients with metastatic breast cancer.

, 2021
Shahan Mamoor
openalex   +2 more sources

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Cancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Ryunosuke Machida, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai   +11 more
wiley   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma

, 2015
Fei Chen, Chuming Fan, Xuezhong Gu, Haixi Zhang, Qian Liu, Xiaoli Gao, Jie Lü, Bao‐Li He, Xun Lai   +8 more
openalex   +2 more sources

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab [PDF]

, 2005
Hasan Tahir
openalex   +1 more source

Hemagophagocytic Lymphohistiocytosis Associated with Recurrent Babesiosis with Lyme Disease Co-Infection in an Immunocompromised Host on Anti-CD20 Monoclonal Antibody Therapy: A Case Report

, 2022
Aleena Zahra, Luis A. Marcos
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic Diseases. [PDF]

CPT Pharmacometrics Syst Pharmacol
Nakada T, Mager DE.
europepmc   +1 more source